Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.

Detailed Description
-----------------
Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China. We operated a multicenter cross-sectional study of subjects who underwent health checkup at nine International Healthcare Centers in China. All participants underwent gastroscopy and pathological examination, serum PG, 13C-urea breath test, and/or Hp serological current infection marker rapid test, all on the same day. PG related parameters were analyzed in different Hp subgroups and regions.

Official Title
-----------------
China Health Promotion Foundation/the Second Affiliated Hospital of Zhejiang University, School of Medicine

Conditions
-----------------
Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection

Intervention / Treatment
-----------------
* Diagnostic Test: pepsinogen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intention to undergo gastroscopy during health checkup examination 25-75 years of age. Exclusion Criteria: a history of gastric ulcer, gastric polyp, or GC a history of gastrectomy treatment with a proton pump inhibitor in the last month contraindications to gastroscopy a history of Hp eradication a history of abdominal pain, abdominal distention, belching, acid reflux, nausea and other digestive tract symptoms within 1 month incomplete data.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-atrophic gastritis<br>No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment) | |
| mild-moderate atrophic gastritis<br>The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment) | |
| severe atrophic gastritis<br>The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment) | Diagnostic Test: pepsinogen<br>* serum pepsinogen diagnosed gastric cancer and precanceous lesion<br>|
| gastric cancer<br>gastric cancer | Diagnostic Test: pepsinogen<br>* serum pepsinogen diagnosed gastric cancer and precanceous lesion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum pepsinogen levels for GC and precancerous lesions | cutoff values of pepsinogen level for GC and precancerous lesions in different regions in China and in different HP status | 1 year | 
| Risk factors for GC | the risk factors for GC, according to the logistic regression model | 1 year |